1. AB0785 Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 patients with psoriatic arthritis in 3 large, phase iii, long-term studies. (15th June 2017) Authors: Mease, PJ; Gladman, DD; Gomez-Reino, JJ; Hall, S; Kavanaugh, A; Lespessailles, E; Schett, G; Paris, M; Teng, L; Wollenhaupt, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0512 Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (156-week) improvements in basdai in psoriatic arthritis patients: pooled results from 3 phase iii, randomized, controlled trials. (15th June 2017) Authors: Mease, PJ; Marzo-Ortega, H; Poder, A; Bosch, F Van den; Wollenhaupt, J; Lespessailles, E; McIlraith, M; Teng, L; Hall, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 683 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial. (15th June 2017) Authors: Nash, P; Ohson, K; Walsh, J; Delev, N; Nguyen, D; Teng, L; Gomez-Reino, JJ; Aelion, JA Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0513 Long-term (156 weeks) improvements in physical function of dmard-naÏve and dmard/biologic-experienced psoriatic arthritis patients treated with apremilast: data from a large database of 4 phase iii clinical trials. (15th June 2017) Authors: Mease, PJ; Wells, A; Wollenhaupt, J; Hall, S; Bosch, F Van den; Lespessailles, E; McIlraith, M; Nguyen, D; Teng, L; Edwards, CJ Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 684 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis. (15th June 2017) Authors: Edwards, CJ; Blanco, FJ; Crowley, J; McIlraith, M; Paris, M; Delev, N; Teng, L; Birbara, CA Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 672 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0436 Durability of apremilast response in patients with psoriatic arthritis: long-term (208-week) results from the palace 1 trial. (15th June 2017) Authors: Kavanaugh, A; Gladman, DD; Gomez-Reino, JJ; Hall, S; Lespessailles, E; Mease, PJ; Schett, G; McIlraith, M; Delev, N; Paris, M; Teng, L; Wollenhaupt, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 023 Transcriptional regulation of p40PHOX and p47PHOX expression via HBP1 in endothelial cells. Issue 4 (1st March 2010) Authors: Teng, L; Li, J-M Journal: Heart Issue: Volume 96:Issue 4(2010) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 007 Roles of P47phox S303/S304 phosphorylation in TNFα-induced endothelial reactive oxygen species production and mitogen-activated protein kinase activation. Issue 4 (1st March 2010) Authors: Teng, L; Li, J-M Journal: Heart Issue: Volume 96:Issue 4(2010) Page Start: e2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗